Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Summary

The purpose of this study is to look at the clinical benefit of carboplatin and paclitaxel and correlate response to study treatment with biologic parameters (i.e. lab studies of blood, urine, or tissue). It is hoped that this will allow researchers to gain insight into the underlying biology of prostate tumor progression and perhaps predict which patients may benefit from this chemotherapy regimen.

Timeline

Start

2011-03

Primary completion

2012-06

Completion

2013-11

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual”

Drugs

Indications